Table 1.
Patient Characteristics (n = 151)
| Age in years, median (range) | 60 (19–86) |
| Female sex | 56 (37) |
| Primary cancer site | |
| Gastrointestinal | 58 (38%) |
| Respiratory | 33 (22%) |
| Genitourinary | 16 (11%) |
| Head and neck | 15 (10%) |
| Other | 29 (19%) |
| Stage IV disease | 147 (97%) |
| Body Mass Index, median (Q1–Q3) | 21 (19–24) |
| Adjusted weight loss over the preceding 100 days in kg, median (Q1–Q3) | 5.9 (3.2–9) |
| Adjusted % weight loss over the preceding 100 days in kg, median (Q1–Q3) | 9 (4.5–12.8) |
| Hypermetabolic statea | 24 (41%) |
| Edmonton Symptom Assessment Scale | |
| Pain | 3 (1–6) |
| Fatigue | 5 (4–8) |
| Nausea | 1 (0–3) |
| Depression | 1 (0–4) |
| Anxiety | 1 (0–4) |
| Drowsiness | 2 (0–5) |
| Appetite | 7 (4–9) |
| Well–being | 5 (3–6) |
| Dyspnea | 2 (0–4) |
| Sleep | 4 (1–7) |
| Active cancer treatment | 97 (64%) |
| On appetite stimulants prior to clinic referral (e.g., megestrol, corticosteroids, dronabinol) | (33%) |
| Albumin <3.5 g/dL | 46 (35%) |
a
defined as measured resting energy expenditure by indirect calorimetry >110% predicted.
Numbers in parentheses are ranges unless specified as a percentage.